Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Ibrutinib in High Risk Chronic Lymphocytic Leukemia
NCT03514017Phase 2Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- May 2019
- Primary completion
- May 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, ibrutinib in chronic lymphocytic leukemia (CLL), sponsored by Moffitt Cancer Center. Started May 2019; status: terminated.
02
Drugs
pembrolizumabibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03514017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03514017.